Nutraceuticals for blood pressure control

Annals of Medicine

Volumn 47, Issue 6, 2015, Pages 447-456

  Sirtori, Cesare R ^a   Arnoldi, Anna ^a   Cicero, Arrigo F G ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Beetroot juice; blood pressure; chocolate; dietary peptides; dietary supplements; hypertension; nutraceuticals

Indexed keywords

AMINO ACID; ARGININE; ASCORBIC ACID; FLAVANOL DERIVATIVE; FLAVONOID; GARLIC EXTRACT; MELATONIN; MINERAL; NUTRACEUTICAL; OMEGA 3 FATTY ACID; PEPTIDE; POTASSIUM; PROBIOTIC AGENT; PROTEIN; RESVERATROL; UBIDECARENONE; VITAMIN D;

ANTIHYPERTENSIVE ACTIVITY; BEETROOT; BLOOD PRESSURE REGULATION; CACAO; CARDIOVASCULAR RISK; COFFEE; EXPERIMENTAL STUDY; FAT INTAKE; HUMAN; LINSEED; META ANALYSIS (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TEA; BLOOD PRESSURE; DIET THERAPY; DIETARY SUPPLEMENT; DRUG EFFECTS; HYPERTENSION; RISK FACTOR;

BLOOD PRESSURE; DIETARY SUPPLEMENTS; HUMANS; HYPERTENSION; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84942988778     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2015.1078905     Document Type: Review

References (123)

1. Gaziano TA. Cardiovascular disease in the developing world and its cost-eff ective management. Circulation. 2005; 112: 3547-53.
2. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet. 2005; 365: 217-23.
3. Lawes CM, Vander Hoorn S, Rodgers A; International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet. 2008; 371: 1513-18.
4. M cInnes G T. L owering blood pressure for cardiovascular risk reduction. J Hypertens Suppl. 2005; 23: S3-8.
5. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Pressure. 2014; 23: 3-16.
6. Appel LJ, Giles TD, Black HR, Izzo JL Jr, Materson BJ, Oparil S, et al. ASH position paper: dietary approaches to lower blood pressure. J Am Soc Hypertens. 2010; 4: 79-89.
7. Miller ER 3rd, Erlinger TP, Appel LJ. The eff ects of macronutrients on blood pressure and lipids: An overview of the DASH and OmniHeart trials. Curr Atheroscler Rep. 2006; 8: 460-5.
8. Domenech M, Roman P, Lapetra J, Garcia de la Corte FJ, Sala-Vila A, de la Torre R, et al. Mediterranean diet reduces 24-hour ambulatory blood pressure, blood glucose, and lipids: one-year randomized, clinical trial. Hypertension. 2014; 64: 69-76.
9. Altorf-van der Kuil W, Engberink MF, Brink EJ, van Baak MA, Bakker SJ, Navis G, et al. Dietary protein and blood pressure: A systematic review. PLoS One. 2010; 5: e12102.
10. Liu XX, Li SH, Chen JZ, Sun K, Wang XJ, Wang XG, et al. Eff ect of soy isofl avones on blood pressure: A meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2012; 22: 463-70.
11. Korhonen H. Milk-derived bioactive peptides: from science to applications. Journal of Functional Foods. 2009; 1: 177-87.
12. Hernandez-Ledesma B, del Mar Contreras M, Recio I. Antihypertensive peptides: production, bioavailability and incorporation into foods. Adv Colloid Interface Sci. 2011; 165: 23-35.
13. Vermeirssen V, Van Camp J, Verstraete W. Bioavailability of angiotensin I converting enzyme inhibitory peptides. Br J Nutr. 2004; 92: 357-66.
14. He R, Aluko RE, Ju XR. Evaluating molecular mechanism of hypotensive peptides interactions with renin and angiotensin converting enzyme. PLoS One. 2014; 9: e91051.
15. Pripp AH. Eff ect of peptides derived from food proteins on blood pressure: A meta-analysis of randomized controlled trials. Food Nutr Res. 2008; 52.
16. Cicero AF, Gerocarni B, Laghi L, Borghi C. Blood pressure lowering eff ect of lactotripeptides assumed as functional foods: A meta-analysis of current available clinical trials. J Hum Hypertens. 2011; 25: 425-36.
17. Cicero AF, Aubin F, Azais-Braesco V, Borghi C. Do the lactotripeptides isoleucine-proline-proline and valine-proline-proline reduce systolic blood pressure in European subjects? A meta-analysis of randomized controlled trials. Am J Hypertens. 2013; 26: 442-9.
18. Udenigwe CC, Aluko RE. Food protein-derived bioactive peptides: production, processing, and potential health benefi ts. J Food Sci. 2012; 77: R11-24.
19. Boschin G, Scigliuolo GM, Resta D, Arnoldi A. ACE-inhibitory activity of enzymatic protein hydrolysates from lupin and other legumes. Food Chem. 2014; 145: 34-40.
20. Arnoldi A, Zanoni C, Lammi C, Boschin G. The role of grain legumes in the prevention of hypercholesterolemia and hypertension. Critic Rev Plant Sci. 2015; 34: 144-68.
21. Wu J Ding X. Characterization of inhibition and stability of soyprotein-derived angiotensin I-converting enzyme inhibitory peptides. Food Res Int. 2002; 35: 367-75.
22. Wu J, Aluko RE, Muir AD. Production of angiotensin I-converting enzyme inhibitory peptides from defatted canola meal. Bioresour Technol. 2009; 100: 5283-7.
23. Li H, Prairie N, Udenigwe CC, Adebiyi AP, Tappia PS, Aukema HM, et al. Blood pressure lowering eff ect of a pea protein hydrolysate in hypertensive rats and humans. J Agric Food Chem. 2011; 59: 9854-60.
24. Quist EE, Phillips RD, Saalia FK. Angiotensin converting enzyme inhibitory activity of proteolytic digests of peanut (Arachis hypogaea L.) fl our. LWT Food Science and Technology. 2009; 42: 694-9.
25. Girgih AT, Udenigwe C, Li H, Adebiyi AP, Aluko RE. Kinetics of enzyme inhibition and antihypertensive eff ects of hemp seed (Cannabis sativa L.) protein hydrolysates. J Am Oil Chem Soc. 2011; 88: 1767-74.
26. Boschin G, Scigliuolo GM, Resta D, Arnoldi A. Optimization of the enzymatic hydrolysis of lupin (Lupinus) proteins for producing ACEinhibitory peptides. J Agric Food Chem. 2014; 62: 1846-51.
27. R ajapakse N W, M attson D L. R ole of L-arginine in nitric oxide production in health and hypertension. Clin Exp Pharmacol Physiol. 2009; 36: 249-55.
28. Cicero AF, Ertek S, Borghi C. Omega-3 polyunsaturated fatty acids: their potential role in blood pressure prevention and management. Curr Vasc Pharmacol. 2009; 7: 330-7.
29. Pase MP, Grima NA, Sarris J. Do long-chain n-3 fatty acids reduce arterial stiff ness? A meta-analysis of randomised controlled trials. Br J Nutr. 2011; 106: 974-80.
30. B alakumar P, T aneja G. F ish oil and vascular endothelial protection: bench to bedside. Free Radic Biol Med. 2012; 53: 271-9.
31. Whelton PK, He J. Potassium in preventing and treating high blood pressure. Semin Nephrol. 1999; 19: 494-9.
32. Gu D, He J, Wu X, Duan X, Whelton PK. Eff ect of potassium supplementation on blood pressure in Chinese: A randomized, placebo-controlled trial. J Hypertens. 2001; 19: 1325-31.
33. D'Elia L, Barba G, Cappuccio FP, Strazzullo P. Potassium intake, stroke, and cardiovascular disease a meta-analysis of prospective studies. J Am Coll Cardiol. 2011; 57: 1210-19.
34. Yang Q, Liu T, Kuklina EV, Flanders WD, Hong Y, Gillespie C, et al. Sodium and potassium intake and mortality among US adults: prospective data from the Th ird National Health and Nutrition Examination Survey. Arch Intern Med. 2011; 171: 1183-91.
35. Houston MC. The importance of potassium in managing hypertension. Curr Hypertens Rep. 2011; 13: 309-17.
36. Kass L, Weekes J, Carpenter L. Eff ect of magnesium supplementation on blood pressure: A meta-analysis. Eur J Clin Nutr. 2012; 66: 411-18.
37. Laurant P, Touyz RM. Physiological and pathophysiological role of magnesium in the cardiovascular system: implications in hypertension. J Hypertens. 2000; 18: 1177-91.
38. Houston MC. The role of magnesium in hypertension and cardiovascular disease. J Clin Hypertens. 2011; 13: 843-7.
39. Hofmeyr G, Lawrie TA, Atallah AN, Duley L, Torloni MR. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2014; 6: CD001059.
40. Ness AR, Khaw KT, Bingham S, Day NE. Vitamin C status and blood pressure. J Hypertens. 1996; 14: 503-8.
41. Ness AR, Chee D, Elliott P. Vitamin C and blood pressure-an overview. J Hum Hypertens. 1997; 11: 343-50.
42. Block G, Mangels AR, Norkus EP, Patterson BH, Levander OA, Taylor PR. Ascorbic acid status and subsequent diastolic and systolic blood pressure. Hypertension. 2001; 37: 261-7.
43. Sherman DL, Keaney JF Jr, Biegelsen ES, Duff y SJ, Coff man JD, Vita JA. Pharmacological concentrations of ascorbic acid are required for the benefi cial eff ect on endothelial vasomotor function in hypertension. Hypertension. 2000; 35: 936-41.
44. Juraschek SP, Guallar E, Appel LJ, Miller ER 3rd. Eff ects of vitamin C supplementation on blood pressure: A meta-analysis of randomized controlled trials. Am J Clin Nutr. 2012; 95: 1079-88.
45. Mahajan AS, Babbar R, Kansal N, Agarwal SK, Ray PC. Antihypertensive and antioxidant action of amlodipine and vitamin C in patients of essential hypertension. J Clin Biochem Nutr. 2007; 40: 141-7.
46. P lantinga Y, G hiadoni L, M agagna A, G iannarelli C, F ranzoni F, T addei S, et al. Supplementation with vitamins C and E improves arterial stiff-ness and endothelial function in essential hypertensive patients. Am J Hypertens. 2007; 20: 392-7.
47. Hatzitolios A, Iliadis F, Katsiki N, Baltatzi M. Is the anti-hypertensive eff ect of dietary supplements via aldehydes reduction evidence based? A systematic review. Clin Exp Hypertens. 2008; 30: 628-39.
48. Leclerc PC, Proulx CD, Arguin G, Belanger S, Gobeil F Jr, Escher E, et al. Ascorbic acid decreases the binding affi nity of the AT1 receptor for angiotensin II. Am J Hypertens. 2008; 21: 67-71.
49. Kim DH, Sabour S, Sagar UN, Adams S, Whellan DJ. Prevalence of hypovitaminosis D in cardiovascular diseases (from the National Health and Nutrition Examination Survey 2001 to 2004). Am J Cardiol. 2008; 102: 1540-4.
50. Vaidya A, Forman JP. Vitamin D and vascular disease: the current and future status of vitamin D therapy in hypertension and kidney disease. Curr Hypertens Rep. 2012; 14: 111-19.
51. M cFarland L V. M eta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium diffi cile disease. Am J Gastroenterol. 2006; 101: 812-22.
52. Tabuchi M, Ozaki M, Tamura A, Yamada N, Ishida T, Hosoda M, et al. Antidiabetic eff ect of Lactobacillus GG in streptozotocin-induced diabetic rats. Biosci Biotechnol Biochem. 2003; 67: 1421-4.
53. Seppo L, Jauhiainen T, Poussa T, Korpela R. A fermented milk high in bioactive peptides has a blood pressure-lowering eff ect in hypertensive subjects. Am J Clin Nutr. 2003; 77: 326-30.
54. Khalesi S, Sun J, Buys N, Jayasinghe R. Eff ect of probiotics on blood pressure: A systematic review and meta-analysis of randomized, controlled trials. Hypertension. 2014; 64: 897-903.
55. Kean B. The blood pressure of the Kuna Indians. Am J Trop Med Hyg. 1944; 24: 341-3.
56. Hollenberg NK, Martinez G, McCullough M, Meinking T, Passan D, Preston M, et al. Aging, acculturation, salt intake, and hypertension in the Kuna of Panama. Hypertension. 1997; 29(1 Pt 2): 171-6.
57. McCullough ML, Chevaux K, Jackson L, Preston M, Martinez G, Schmitz HH, et al. Hypertension, the Kuna, and the epidemiology of fl avanols. J Cardiovasc Pharmacol. 2006; 47(Suppl 2): S103-9; discussion 19-21.
58. Taubert D, Berkels R, Roesen R, Klaus W. Chocolate and blood pressure in elderly individuals with isolated systolic hypertension. JAMA. 2003; 290: 1029-30.
59. Serafi ni M, Bugianesi R, Maiani G, Valtuena S, De Santis S, Crozier A. Plasma antioxidants from chocolate. Nature. 2003; 424: 1013.
60. Grassi D, Necozione S, Lippi C, Croce G, Valeri L, Pasqualetti P, et al. Cocoa reduces blood pressure and insulin resistance and improves endothelium-dependent vasodilation in hypertensives. Hypertension. 2005; 46: 398-405.
61. Grassi D, Desideri G, Necozione S, Lippi C, Casale R, Properzi G, et al. Blood pressure is reduced and insulin sensitivity increased in glucoseintolerant, hypertensive subjects aft er 15 days of consuming highpolyphenol dark chocolate. J Nutr. 2008; 138: 1671-6.
62. Taubert D, Roesen R, Lehmann C, Jung N, Schomig E. Eff ects of low habitual cocoa intake on blood pressure and bioactive nitric oxide: A randomized controlled trial. JAMA. 2007; 298: 49-60.
63. Flammer AJ, Hermann F, Sudano I, Spieker L, Hermann M, Cooper KA, et al. Dark chocolate improves coronary vasomotion and reduces platelet reactivity. Circulation. 2007; 116: 2376-82.
64. Hollenberg NK, Fisher ND. Is it the dark in dark chocolate? Circulation. 2007; 116: 2360-2.
65. Schroeter H, Heiss C, Balzer J, Kleinbongard P, Keen CL, Hollenberg NK, et al. ( )-Epicatechin mediates benefi cial eff ects of fl avanol-rich cocoa on vascular function in hu ma ns. Proc Natl Acad Sci U S A. 2006; 103: 1024-9.
66. Baba S, Natsume M, Yasuda A, Nakamura Y, Tamura T, Osakabe N, et al. Plasma LDL and HDL cholesterol and oxidized LDL concentrations are altered in normo-and hypercholesterolemic humans aft er intake of diff erent levels of cocoa powder. J Nutr. 2007; 137: 1436-41.
67. di Giuseppe R, Di Castelnuovo A, Centritto F, Zito F, De Curtis A, Costanzo S, et al. Regular consumption of dark chocolate is associated with low serum concentrations of C-reactive protein in a healthy Italian population. J Nutr. 2008; 138: 1939-45.
68. Shiina Y, Funabashi N, Lee K, Toyoda T, Sekine T, Honjo S, et al. Relaxation eff ects of lavender aromatherapy improve coronary fl ow velocity reserve in healthy men evaluated by transthoracic Doppler echocardiography. Int J Cardiol. 2008; 129: 193-7.
69. Janszky I, Mukamal KJ, Ljung R, Ahnve S, Ahlbom A, Hallqvist J. Chocolate consumption and mortality following a fi rst acute myocardial infarction: the Stockholm Heart Epidemiology Program. J Intern Med. 2009; 266: 248-57.
70. Buijsse B, Weikert C, Drogan D, Bergmann M, Boeing H. Chocolate consumption in relation to blood pressure and risk of cardiovascular disease in German adults. Eur Heart J. 2010; 31: 1616-23.
71. Kilander L, Nyman H, Boberg M, Hansson L, Lithell H. Hypertension is related to cognitive impairment: A 20-year follow-up of 999 men. Hypertension. 1998; 31: 780-6.
72. Desideri G, Kwik-Uribe C, Grassi D, Necozione S, Ghiadoni L, Mastroiacovo D, et al. Benefi ts in cognitive function, blood pressure, and insulin resistance through cocoa fl avanol consumption in elderly subjects with mild cognitive impairment: the Cocoa, Cognition, and Aging (CoCoA) study. Hypertension. 2012; 60: 794-801.
73. Mastroiacovo D, Kwik-Uribe C, Grassi D, Necozione S, Raff aele A, Pistacchio L, et al. Cocoa fl avanol consumption improves cognitive function, blood pressure control, and metabolic profi le in elderly subjects: the Cocoa, Cognition, and Aging (CoCoA) Study-a randomized controlled trial. Am J Clin Nutr. 2015; 101: 538-48.
74. Buitrago-Lopez A, Sanderson J, Johnson L, Warnakula S, Wood A, Di Angelantonio E, et al. Chocolate consumption and cardiometabolic disorders: systematic review and meta-analysis. BMJ. 2011; 343: d4488.
75. Zomer E, Owen A, Magliano DJ, Liew D, Reid CM. The eff ectiveness and cost eff ectiveness of dark chocolate consumption as prevention therapy in people at high risk of cardiovascular disease: best case scenario analysis using a Markov model. BMJ. 2012; 344: e3657.
76. Esser D, Mars M, Oosterink E, Stalmach A, Muller M, Afman LA. Dark chocolate consumption improves leukocyte adhesion factors and vascular function in overweight men. FASEB J. 2014; 28: 1464-73.
77. EFSA. Scientifi c Opinion on the substantiation of a health claim related to cocoa fl avanols and maintenance of normal endotheliumdependent vasodilation pursuant to Article 13(5) of Regulation (EC) No1924/2006. EFSA Journal. 2012; 10: 2809.
78. EFSA. Scientifi c Opinion on the modifi cation of the authorsation of a health claim related to cocoa fl avanols and maintenance of normal endothelium-dependent vasodilation pursuant to Article 13(5) of Regulation (EC) No1924/2006 following a request in accordance with Article 19 of Regulation (EC) No 1924/2006. E FSA Journal. 2 014; 1 2: 3 654.
79. Joshipura KJ, Ascherio A, Manson JE, Stampfer MJ, Rimm EB, Speizer FE, et al. Fruit and vegetable intake in relation to risk of ischemic stroke. JAMA. 1999; 282: 1233-9.
80. Larsen FJ, Ekblom B, Sahlin K, Lundberg JO, Weitzberg E. Eff ects of dietary nitrate on blood pressure in healthy volunteers. New Engl J Med. 2006; 355: 2792-3.
81. Webb AJ, Patel N, Loukogeorgakis S, Okorie M, Aboud Z, Misra S, et al. Acute blood pressure lowering, vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion to nitrite. Hypertension. 2008; 51: 784-90.
82. Kanner J, Harel S, Granit R. Betalains-a new class of dietary cationized antioxidants. J Agric Food Chem. 2001; 49: 5178-85.
83. Hobbs DA, Kaff a N, George TW, Methven L, Lovegrove JA. Blood pressure-lowering eff ects of beetroot juice and novel beetroot-enriched bread products in normotensive male subjects. Br J Nutr. 2012; 108: 2066-74.
84. Ghosh SM, Kapil V, Fuentes-Calvo I, Bubb KJ, Pearl V, Milsom AB, et al. Enhanced vasodilator activity of nitrite in hypertension: critical role for erythrocytic xanthine oxidoreductase and translational potential. Hypertension. 2013; 61: 1091-102.
85. K apil V, K hambata R S, R obertson A, C aulfi eld MJ, Ahluwalia A. Dietary nitrate provides sustained blood pressure lowering in hypertensive patients: A randomized, phase 2, double-blind, placebo-controlled study. Hypertension. 2015; 65: 320-7.
86. Muggeridge DJ, Howe CC, Spendiff O, Pedlar C, James PE, Easton C. A single dose of beetroot juice enhances cycling performance in simulated altitude. Med Sci Sports Exerc. 2014; 46: 143-50.
87. Kelly J, Vanhatalo A, Bailey SJ, Wylie LJ, Tucker C, List S, et al. Dietary nitrate supplementation: eff ects on plasma nitrite and pulmonary O2 uptake dynamics during exercise in hypoxia and normoxia. Am J Physiol Regul Integr Comp Physiol. 2014; 307: R920-30.
88. Arnold JT, Oliver SJ, Lewis-Jones TM, Wylie LJ, Macdonald JH. Beetroot juice does not enhance altitude running performance in welltrained athletes. Appl Physiol Nutr Metab. 2015; 40: 590-5.
89. Steff en M, Kuhle C, Hensrud D, Erwin PJ, Murad MH. The eff ect of coff ee consumption on blood pressure and the development of hypertension: A systematic review and meta-analysis. J Hypertens. 2012; 30: 2245-54.
90. Watanabe T, Arai Y, Mitsui Y, Kusaura T, Okawa W, Kajihara Y, et al. The blood pressure-lowering eff ect and safety of chlorogenic acid from green coff ee bean extract in essential hypertension. Clin Exp Hypertens. 2006; 28: 439-49.
91. Yamaguchi T, Chikama A, Mori K, Watanabe T, Shioya Y, Katsuragi Y, et al. Hydroxyhydroquinone-free coff ee: A double-blind, randomized controlled dose-response study of blood pressure. Nutr Metab Cardiovasc Dis. 2008; 18: 408-14.
92. Revuelta-Iniesta R, Al-Dujaili EA. Consumption of green coff ee reduces blood pressure and body composition by infl uencing 11beta-HSD1 enzyme activity in healthy individuals: A pilot crossover study using green and black coff ee. Biomed Res Int. 2014; 2014: 482704.
93. Moreno-Luna R, Munoz-Hernandez R, Miranda ML, Costa AF, Jimenez-Jimenez L, Vallejo-Vaz AJ, et al. Olive oil polyphenols decrease blood pressure and improve endothelial function in young women with mild hypertension. Am J Hypertens. 2012; 25: 1299-304.
94. P errinjaquet-Moccetti T, B usjahn A, S chmidlin C, S chmidt A, B radl B, Aydogan C. Food supplementation with an olive (Olea europaea L.) leaf extract reduces blood pressure in borderline hypertensive monozygotic twins. Phytother Res. 2008; 22: 1239-42.
95. Susalit E, Agus N, Eff endi I, Tjandrawinata RR, Nofi arny D, Perrinjaquet-Moccetti T, et al. Olive (Olea europaea) leaf extract eff ective in patients with stage-1 hypertension: comparison with Captopril. Phytomedicine. 2011; 18: 251-8.
96. Ried K, Fakler P. Protective eff ect of lycopene on serum cholesterol and blood pressure: meta-analyses of intervention trials. Maturitas. 2011; 68: 299-310.
97. P aran E, N ovack V, E ngelhard Y N, H azan-Halevy I. The eff ects of natural antioxidants from tomato extract in treated but uncontrolled hypertensive patients. Cardiovasc Drugs Th er. 2009; 23: 145-51.
98. Petyaev IM, Dovgalevsky PY, Chalyk NE, Klochkov V, Kyle NH. Reduction in blood pressure and serum lipids by lycosome formulation of dark chocolate and lycopene in prehypertension. Food Sci Nutr. 2014; 2: 744-50.
99. Ried K, Frank OR, Stocks NP, Fakler P, Sullivan T. Eff ect of garlic on blood pressure: A systematic review and meta-analysis. BMC Cardiovasc Disord. 2008; 8: 13.
100. Ried K, Frank OR, Stocks NP. Aged garlic extract lowers blood pressure in patients with treated but uncontrolled hypertension: A randomised controlled trial. Maturitas. 2010; 67: 144-50.
101. Langsjoen PH, Langsjoen AM. Overview of the use of CoQ10 in cardiovascular disease. BioFactors. 1999; 9: 273-84.
102. Ho MJ, Bellusci A, Wright JM. Blood pressure lowering effi cacy of coenzyme Q10 for primary hypertension. Cochrane Database Syst Rev. 2009; (4): CD007435.
103. Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, et al. Coenzyme Q10 in the treatment of hypertension: A meta-analysis of the clinical trials. J Hum Hypertens. 2007; 21: 297-306.
104. Maimoona A, Naeem I, Saddiqe Z, Jameel K. A review on biological, nutraceutical and clinical aspects of French maritime pine bark extract. J Ethnopharmacol. 2011; 133: 261-77.
105. Liu X, Wei J, Tan F, Zhou S, Wurthwein G, Rohdewald P. Pycnogenol, French maritime pine bark extract, improves endothelial function of hypertensive patients. Life Sci. 2004; 74: 855-62.
106. Zibadi S, Rohdewald PJ, Park D, Watson RR. Reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycnogenol supplementation. Nutr Res. 2008; 28: 315-20.
107. Hosseini S, Lee J, Sepulveda RT, Rohdewald P, Watson RR. A randomized, double-blind, placebo-controlled, prospective, 16 week crossover study to determine the role of Pycnogenol in modifying blood pressure in mildly hypertensive patients. Nutr Res. 2001; 21: 1251-60.
108. Enseleit F, Sudano I, Periat D, Winnik S, Wolfrum M, Flammer AJ, et al. Eff ects of Pycnogenol on endothelial function in patients with stable coronary artery disease: A double-blind, randomized, placebo-controlled, cross-over study. Eur Heart J. 2012; 33: 1589-97.
109. Rodella LF, Favero G, Foglio E, Rossini C, Castrezzati S, Lonati C, et al. Vascular endothelial cells and dysfunctions: role of melatonin. Front Biosci (Elite Ed). 2013; 5: 119-29.
110. G rossman E, L audon M, Z isapel N. E ff ect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vasc Health Risk Manag. 2011; 7: 577-84.
111. Scheer FA, Morris CJ, Garcia JI, Smales C, Kelly EE, Marks J, et al. Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: A randomized controlled trial. Sleep. 2012; 35: 1395-402.
112. C aligiuri S P, E del A L, A liani M, P ierce G N. F laxseed for hypertension: implications for blood pressure regulation. Curr Hypertens Rep. 2014; 16: 499.
113. K halesi S, I rwin C, S chubert M. F laxseed consumption may reduce blood pressure: A systematic review and meta-analysis of controlled trials. J Nutr. 2015; 145: 758-65.
114. Caligiuri SP, Aukema HM, Ravandi A, Guzman R, Dibrov E, Pierce GN. Flaxseed consumption reduces blood pressure in patients with hypertension by altering circulating oxylipins via an alpha-linolenic acidinduced inhibition of soluble epoxide hydrolase. Hypertension. 2014; 64: 53-9.
115. Li H, Xia N, Forstermann U. Cardiovascular eff ects and molecular targets of resveratrol. Nitric Oxide. 2012; 26: 102-10.
116. Mattison JA, Wang M, Bernier M, Zhang J, Park SS, Maudsley S, et al. Resveratrol prevents high fat/sucrose diet-induced central arterial wall infl ammation and stiff ening in nonhuman primates. Cell Metab. 2014; 20: 183-90.
117. Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, Stodkilde-Jorgensen H, et al. High-dose resveratrol supplementation in obese men: An investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes. 2013; 62: 1186-95.
118. Feringa HH, Laskey DA, Dickson JE, Coleman CI. The eff ect of grape seed extract on cardiovascular risk markers: A meta-analysis of randomized controlled trials. J Am Diet Assoc. 2011; 111: 1173-81.
119. Sahebkar A, Serban C, Ursoniu S, Wong ND, Muntner P, Graham IM, et al. Lack of effi cacy of resveratrol on C-reactive protein and selected cardiovascular risk factors-Results from a systematic review and metaanalysis of randomized controlled trials. Int J Cardiol. 2015; 189: 47-55
120. Onakpoya I, Spencer E, Heneghan C, Th 120. ompson M. The eff ect of green tea on blood pressure and lipid profi le: A systematic review and metaanalysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2014; 24: 823-36.
121. Liu G, Mi XN, Zheng XX, Xu YL, Lu J, Huang XH. Eff ects of tea intake on blood pressure: A meta-analysis of randomised controlled trials. Br J Nutr. 2014; 112: 1043-54.
122. de Jesus Romero-Prado MM, Curiel-Beltran JA, Miramontes-Espino MV, Cardona-Munoz EG, Rios-Arellano A, Balam-Salazar L. Dietary fl avonoids added to pharmacological antihypertensive therapy are eff ective in improving blood pressure. Basic Clin Pharmacol Toxicol. 2015; 117: 57-64.
123. Cicero AF, Borghi C. Evidence of clinically relevant effi cacy for dietary supplements and nutraceuticals. Curr Hypertens Rep. 2013; 15: 260-7.